Evidence Gaps

Naftopidil vs tamsulosin

Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 965 participants
Moderate

Naftopidil vs propiverine (anticholinergic)

Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 37 participants
Low

Naftopidil vs Eviprostat (phytotherapy)

Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 49 participants
Moderate

Naftopidil vs silodosin (alpha‐blocker)

Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 652 participants
Low